Silodosin
|
WikiDoc Resources for Silodosin |
|
Articles |
|---|
|
Most recent articles on Silodosin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Silodosin at Clinical Trials.gov Clinical Trials on Silodosin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Silodosin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Silodosin Discussion groups on Silodosin Directions to Hospitals Treating Silodosin Risk calculators and risk factors for Silodosin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Silodosin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Silodosin is an α1-adrenoceptor antagonist with high uroselectivity. It appears to be more effective than tamsulosin in relieving urinary symptoms associated with benign prostatic hyperplasia (BPH).